Cellectis S.a Stock News

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS ) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR target and development in China by Cytovia''s joint venture entity, CytoLynx Therapeutics . The amended financial terms include an equity Full story available on Benzinga.com

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR tar

Cytovia Commits to Additional Milestones and Equity grant Cytovia Commits to Additional Milestones and Equity grant

Cellectis S.A. (NASDAQ:CLLS) was the target of a large decline in short interest in October. As of October 29th, there was short interest totalling 597,800 shares, a decline of 38.0% from the October 14th total of 964,500 shares. Based on an average daily volume of 201,600 shares, the days-to-cover ratio is currently 3.0 days. Approximately []

Coave Therapeutics appoints Chief Medical Officer and Chief Operating Officer Submitted 15/11/2021 - 9:15am Coave Therapeutics (Coave), a clinical-stage biotechnology company backed by international life science and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, Sham Innovation Santé/Turenne, has strengthened its leadership team with the appointments of Thomas Blaettler MD, as Chief Medical Officer, and Patricia Françon PhD, to the newly created position of Chief Operating Officer. I am very pleased to welcome Thomas and Patricia to the leadership team at Coave. Their collective accomplishments and deep domain expertise in neuroscience, cell and gene therapy, in addition to their extensive clinical drug development and project management experience will be invaluable as we progress our lead candidate through clinical development and advance our pipeline of novel gene therapies into clinical development targeting rare Ocular and CNS diseases, says Rodolphe Clerval, CEO.

Analysts expect Cellectis S.A. (NASDAQ:CLLS) to report $12.30 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Cellectis earnings, with the lowest sales estimate coming in at $11.59 million and the highest estimate coming in at $13.00 million. Cellectis posted sales of $15.63 million in the same quarter last []

Zacks Investment Research downgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a sell rating in a report released on Wednesday morning, Zacks.com reports. According to Zacks, Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. []

Cellectis S.A. (CLLS) CEO Andre Choulika on Q3 2021 Results - Earnings Call Transcript

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs u

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared

NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs u

Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results - Earnings Call Transcript

• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients.

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs�

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential